Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire resubmits methylphenidate patch

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Shire and partner Noven's response to an April 2003 "not approvable" letter for their methylphenidate transdermal patch for attention deficit hyperactivity disorder has been accepted by FDA, the firms announce July 26. The NDA was resubmitted June 28. Included in the submission are two additional studies: a 270-patient Phase III trial and a 79-patient Phase II trial. Both studies were seven weeks and enrolled children between six and 12 years of age. The sponsors are seeking an indication for treatment of that age group in the new NDA. The product, formerly MethyPatch, would be the first methylphenidate product available in patch form...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel